Beam Therapeutics Inc

Research Beam Therapeutics Inc (BEAM) on Bullrun: market cap USD 3.19B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 3.19B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 139.74M-USD 79.99M-USD 360.05Mn/a-0.81USD 294.94MUSD 154.12MUSD 1.24B
FY2024USD 63.52M-USD 376.74M-USD 356.19Mn/a-4.58USD 281.97MUSD 161.43MUSD 733.55M
FY2023USD 377.71M-USD 132.53M-USD 182.93Mn/a-1.72USD 435.90MUSD 172.69MUSD 981.33M
FY2022USD 60.92M-USD 289.09M-USD 26.42Mn/a-4.13USD 232.77MUSD 173.50MUSD 733.47M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 3.19Bn/an/an/a
20252025-12-31USD 2.82Bn/an/an/a
20242024-12-31USD 2.07Bn/an/an/a
20232023-12-29USD 2.22Bn/an/an/a
20222022-12-30USD 2.76Bn/an/an/a
20212021-12-31USD 5.45Bn/an/an/a

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Beam Therapeutics Inc's market cap?

Beam Therapeutics Inc's market capitalization is USD 3.19B.

What does Beam Therapeutics Inc do?

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.